A Mount Sinai-led research team has discovered a new kind of stem cell that can become either a liver cell or a cell that lines liver blood vessels, according to a study published today in the journal Stem Cell Reports. The existence of such a cell type contradicts current theory on how organs arise from cell layers in the embryo, and may hold clues to origins of, and future treatment for, liver cancer.
Thanks to stem cells, humans develop from a single cell into a complex being made up of more than 200 cell types. The original, single human stem cell, the fertilized embryo, has the potential to develop into every kind of human cell. Stem cells multiply (proliferate) and specialize (differentiate) until millions of functional cells result, including liver cells (hepatocytes), blood vessel cells (endothelial cells), muscle cells, bone cells, etc.
In the womb, the human embryo early on becomes three "germ" layers of stem cells - the endoderm, mesoderm and ectoderm. The long-held consensus was that the endoderm goes on to form the liver and other gut organs; the mesoderm the heart, muscles and blood cells; and the ectoderm the brain and skin. Researchers have sought to determine the germ layer that yields each organ because these origins hold clues to healthy function and disease mechanisms in adults.
"We found a stem cell that can become either a liver cell, which is thought to originate in the endoderm, or an endothelial cell that helps to from a blood vessel, which was thought to derive from the mesoderm," said Valerie Gouon-Evans, PhD, Assistant Professor in the Department of Developmental and Regenerative Biology and Black Family Stem Cell Institute, Icahn School of Medicine at Mount Sinai, and lead author for the study. "Our results go against traditional germ layer theory, which holds that a stem cell can only go on to become cell types in line with the germ layer that stem cell came from. Endothelial cells may arise from both the endoderm and mesoderm."
Cell Growth Plusses and Minuses
Beyond the womb, many human organs contain pools of partially differentiated stem cells, which are ready to differentiate into specific replacement cells as needed. Among these are stem cells that "know" they are liver cells, but have enough "stemness" to become more than one cell type.
By advancing the understanding of stem cell processes in the liver, the study offers insights into mechanisms that drive liver cancer. The rapid growth seen in cells as the fetal liver develops is similar in some ways to the growth seen in tumors. Among the factors that make both possible is the building of blood vessels that supply nutrients and oxygen.
The research team's newfound, liver-based stem cell type has the ability to become part of newly formed blood vessels. Thus, a detailed understanding of it may have "a decisive impact on understanding liver cancer progression," said Dr. Gouon-Evans. If similar bi-potential progenitor cells are found in liver cancers, they may be ideal targets for drugs that eradicate not only their descendant liver cancer cells but also the formation of blood vessels that feed tumors.
The new study also has implications for the field of liver regeneration. Many labs seek to understand how the liver repairs itself when damaged, and many clinical trials to determine whether injecting healthy liver cells into damaged livers can repair them.
Within limits, mature liver cells divide and multiply to supply new cells that replace damaged ones. When the damage is too severe, however, evidence suggests that the organ calls on its stem cell pool, with stem cells multiplying to provide additional replacement cells. Dr. Gouon-Evans and colleagues theorize that their new stem cell type has a role here as well, and further studies are underway to test its therapeutic potential. Using standard tools of molecular biology, the team garnered evidence that the newly discovered stem cell type is present in both human and mouse livers as a fetus develops, and that these cells have a regenerative effect when transplanted into damaged mouse livers.
Along with Dr. Gouon-Evans as corresponding author, the co-first authors of the study were Orit Goldman and Songyan Han, also within the Department of Developmental and Regenerative Biology, along with Wissam Hamou. Also study authors were Vanina Jodon de Villeroche and Georges Uzan of the Hospital Paul Brousse in Villejuif, France, and Heiko Lickert of the Institute of Diabetes and Regeneration Research, Helmholtz Zentrum Munchen, Neuherberg, Germany.
The study was funded by the Black Family Stem Cell Institute and the National Institute of Diabetes and Digestive and Kidney Diseases (R01DK087867-01).
About the Mount Sinai Health System
The Mount Sinai Health System is an integrated health system committed to providing distinguished care, conducting transformative research, and advancing biomedical education. Structured around seven member hospital campuses and a single medical school, the Health System has an extensive ambulatory network and a range of inpatient and outpatient services--from community based facilities to tertiary and quaternary care. The System includes approximately 6,600 primary and specialty care physicians, 12 minority owned free standing ambulatory surgery centers, over 45 ambulatory practices throughout the five boroughs of New York City, Westchester, and Long Island, as well as 31 affiliated community health centers. Physicians are affiliated with the Icahn School of Medicine at Mount Sinai, which is ranked among the top 20 medical schools both in National Institutes of Health funding and by U.S. News & World Report.
For more information, visit http://www.